Non-Homologous DNA End Joining in Anticancer Therapy

Author(s): Elzbieta Pastwa, Mariusz Malinowski.

Journal Name: Current Cancer Drug Targets

Volume 7 , Issue 3 , 2007

Submit Manuscript
Submit Proposal


Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become molecular targets in the treatment of cancer. Inhibition of this pathway leads to radio- and chemosensitization of cancer cells. This review will focus on the new therapeutic strategies for NHEJ pathway inhibition and their application in anticancer therapy.

Keywords: Non-homologous DNA end joining, NHEJ, DNA double-strand breaks, DSBs, DNA-dependent protein kinase, DNA-PK, chemosensitization, radiosensitization

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [243 - 250]
Pages: 8
DOI: 10.2174/156800907780618284
Price: $58

Article Metrics

PDF: 2